Cross‐sectional and Mendelian randomization study of fibroblast growth factor 19 reveals causal associations with metabolic diseases
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16687 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Yan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Mendelian Randomization Analysis, Non-alcoholic Fatty Liver Disease, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Wu Jieping Medical Foundation.
Abstract (Originalsprache)
Background and Aim Fibroblast growth factor 19 (FGF19) is an intestinal‐derived factor that plays a role in metabolic diseases. We performed a differential study of circulating FGF19 levels and investigated the causal effects of FGF19 on metabolic diseases using Mendelian randomization (MR).
Methods
Firstly, 958 subjects were included in the physical examination center of affiliated hospital from January 2019 to January 2021. Dividing the subjects into different subgroups to compare FGF19 levels. We conducted a two‐sample MR analysis of genetically predicted circulating FGF19 in relation to alcohol, cardiovascular and metabolic biomarkers and diseases, and liver function biomarkers using publicly available genome‐wide association study summary statistics data.
Results
The circulating FGF19 levels in nonalcoholic fatty liver disease (NAFLD) patients were lower than those without NAFLD ( P < 0.001). The FGF19 levels in participants with obese were lower than those without obese ( P < 0.001). In two‐sample MR analyses, genetically predicted higher circulating FGF19 levels was significantly associated with lower aspartate aminotransferase, γ‐glutamyltransferase, triglycerides, total cholesterol, low‐density lipoprotein, and C‐reactive protein concentrations ( P < 0.05) and a negative correlation with cardiovascular disease and cirrhosis whereas a positive association with type 2 diabetes mellitus ( P < 0.05).
Conclusions
Our study found that circulating FGF19 levels were lower in NAFLD and obese populations. Additionally, our MR research results support the causal effects of FGF19 on improved liver function, lipids, and reduced the occurrence of inflammation, cardiovascular disease, and cirrhosis. We found a positive correlation with diabetes, which may indicate a compensatory increase in regulating above FGF19 resistance states in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Central Laboratory, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Infectious Diseases, Huaian Hospital of Huaian City, Huaian, Jiangsu, China.
- Department of Infection and Hepatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
ORCID-Profile: Changyong Dai
Förderung
- Wu Jieping Medical Foundation
Zitieren
APA
Li, Y., Dai, C., Yang, H., Zeng, H., Ruan, Y., Dai, M., Hao, J., Wang, L., Yan, X., & Ji, F. (2024). Cross‐sectional and Mendelian randomization study of fibroblast growth factor 19 reveals causal associations with metabolic diseases. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16687
Vancouver
Li Y, Dai C, Yang H, Zeng H, Ruan Y, Dai M, et al. Cross‐sectional and Mendelian randomization study of fibroblast growth factor 19 reveals causal associations with metabolic diseases. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16687
BibTeX
@article{Li2024,
author = {Li, Yan and Dai, Changyong and Yang, Haiqing and Zeng, Huang and Ruan, Yuhua and Dai, Mingjia and Hao, Jungui and Wang, Liping and Yan, Xuebing and Ji, Fang},
title = {Cross‐sectional and Mendelian randomization study of fibroblast growth factor 19 reveals causal associations with metabolic diseases},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16687}
}
EUVIMED